News
ThermoGenesis Announces 1-for-45 Reverse Stock Split
ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2022 and Provide a Corporate Strategic Update
ThermoGenesis Closes $2.05 Million Public Offering
ThermoGenesis Prices $2.05 Million Public Offering
H.C. Wainwright 24th Annual Global Investment Conference (2022)
ThermoGenesis Holdings to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Combining Microbubbles & Cell Sorting for Quick & Efficient Cell Isolation
CGT CDMO: Controlled Cell Manufacturing Meets Controlled Smart Storage Solutions
The Different Approaches to Cell Sorting in the Cell Therapy Manufacturing Process
The Importance of Trust in a Cell and Gene Therapy (CGT) CDMO Relationship
CDMO: The Importance of Closed Systems in the Manufacturing Process
CDMO: The Rise of End-to-End Services
ThermoGenesis BioArchive System: The Best Smart Storage Solution for the Cell Therapy Manufacturing Process
Obstacles Preventing GMP Cell Therapy from Becoming Mainstream
Cryopreservation: A Key Element in the Successful Delivery of GMP Cell Therapies
Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
The Process of Bringing a Clinical Discovery to Market – From Concept to Commercial for Cell and Gene Therapy Products
ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2021, and Provides Corporate Update
